A Study of Remternetug Versus Placebo in Early Alzheimer’s Disease Participants at Risk for Cognitive and Functional Decline
-
Enrollment
This study is currently enrolling. -
Research Area
Neuroscience Research -
Location
-
Principal Investigator
-
Sponsor
Eli Lilly
This study is looking to assess the effect of remternetug versus
placebo on time to clinically meaningful
progression in participants with early AD.
Enrollment Form
This study is currently enrolling.